Elite launches generic methadone tablets, expanding pain portfolio

Elite Pharmaceuticals ( (ELTP) ) has shared an update.

On April 2, 2026, Elite Pharmaceuticals announced it has commercially launched its generic methadone hydrochloride 5 mg and 10 mg tablets in the United States under the Elite Laboratories, Inc. label. The tablets, indicated for severe and persistent pain and for detoxification and maintenance treatment of opioid addiction alongside appropriate social and medical services, enter a market where combined brand and generic retail sales reached about $22 million in 2025, underscoring a modest but meaningful revenue opportunity for the company.

The launch strengthens Elite’s presence in the controlled-substance and pain-management segment of the generic pharmaceuticals market, aligning with its strategy of targeting niche products that require specialized handling and regulatory oversight. For stakeholders, the move suggests incremental top-line growth potential and deeper participation in opioid addiction treatment and chronic pain management markets, albeit in a competitive and tightly regulated therapeutic area.

The most recent analyst rating on (ELTP) stock is a Hold with a $0.42 price target. To see the full list of analyst forecasts on Elite Pharmaceuticals stock, see the ELTP Stock Forecast page.

Spark’s Take on ELTP Stock

According to Spark, TipRanks’ AI Analyst, ELTP is a Outperform.

Score is driven mainly by strong financial performance (high margins, solid TTM profitability, and very low leverage) supported by a low P/E valuation and a positive recent results update. The key drag is weak technicals, with the stock trading below major moving averages and negative MACD indicating a downtrend.

To see Spark’s full report on ELTP stock, click here.

More about Elite Pharmaceuticals

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and distributing niche generic products, particularly oral, controlled-release drug formulations. The company owns multiple generic medicines sold nationwide under the Elite Laboratories, Inc. label, licenses additional products to TAGI Pharma, and operates a cGMP and DEA-registered facility in Northvale, N.J.

Elite’s market positioning centers on serving targeted segments of the U.S. generic drug market where complex formulations and regulatory compliance are key differentiators. By combining in-house development with nationwide distribution and select licensing partnerships, the company aims to expand its portfolio of controlled-substance and pain-management generics while leveraging its specialized manufacturing capabilities.

Average Trading Volume: 731,185

Technical Sentiment Signal: Hold

Current Market Cap: $407M

For detailed information about ELTP stock, go to TipRanks’ Stock Analysis page.